文献速递MDS 与骨髓增殖性肿瘤白血病造血干细胞移植与细胞治疗

在高危MDS和AML减低强度预处理异基因移植后使用维奈克拉/阿扎胞苷预防性维持治疗

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
PubMed 文献 · Blood Adv · 2024-01-01

一项1期试验评估高危MDS/AML患者在接受维奈克拉/氟达拉滨/白消安减低强度异基因移植后,使用维奈克拉/阿扎胞苷预防性维持治疗的安全性和疗效。27例移植患者中22例接受维持治疗,2年总生存率67%、无进展生存率59%、累积复发率41%、非复发死亡率0%,但需随机研究评估潜在获益。

要点

  • 维奈克拉/阿扎胞苷预防性维持治疗在高危MDS/AML移植后可安全给药。
  • 维持治疗期间最常见3-4级不良事件为白细胞减少、中性粒细胞减少和血小板减少,均为短暂且可控。
  • 2年总生存率67%(95%CI 43%-83%),累积复发率41%(95%CI 20%-61%)。

核心结论

  • 本研究表明,高危MDS/AML患者在接受维奈克拉/氟达拉滨/白消安减低强度异基因移植后,可安全给予维奈克拉/阿扎胞苷预防性维持治疗,但需要随机研究来正确评估任何潜在获益。

研究设计与样本

  • 1期试验,评估维奈克拉/阿扎胞苷预防性维持治疗在高危MDS/AML患者中的安全性和疗效。
  • 患者接受维奈克拉/氟达拉滨/白消安(Ven/FluBu2)减低强度异基因移植,以他克莫司和甲氨蝶呤预防移植物抗宿主病。
  • 27例患者接受Ven/FluBu2异基因移植,其中55.6%既往暴露于维奈克拉,96%分子可测量残留病阳性。
  • 22例接受维持治疗:阿扎胞苷36 mg/m2静脉给药第1-5天,维奈克拉400 mg口服第1-14天,按指定剂量方案/水平(42天周期×8或28天周期×12)。

主要发现

  • 维持治疗期间最常见3-4级不良事件为白细胞减少、中性粒细胞减少和血小板减少,均为短暂且可控。
  • 感染不常见(n=4,均为1-2级)。
  • 1年和2年中/重度慢性GVHD发生率分别为4%(95%CI 0.3%-18%)和22%(95%CI 9%-40%)。
  • 在幸存者中位随访25个月后,中位总生存期未达到。
  • 22例接受维奈克拉/阿扎胞苷维持治疗的患者中,2年总生存率、无进展生存率、非复发死亡率和累积复发率分别为67%(95%CI 43%-83%)、59%(95%CI 36%-76%)、0%和41%(95%CI 20%-61%)。

关键数值与推荐

  • 维持治疗方案:阿扎胞苷36 mg/m2静脉给药第1-5天,维奈克拉400 mg口服第1-14天,42天周期×8或28天周期×12。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需要随机研究来正确评估任何潜在获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a phase 1 trial assessing safety and efficacy of prophylactic maintenance therapy with venetoclax and azacitidine (Ven/Aza) for patients with high-risk myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) undergoing reduced intensity allogeneic stem cell transplantation (allo-SCT) after Ven and fludarabine/busulfan conditioning (Ven/FluBu2 allo-SCT) with tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis. Among 27 patients who underwent Ven/FluBu2 allo-SCT (55.6% with prior Ven exposure, and 96% with positive molecular measurable residual disease), 22 received maintenance therapy with Aza 36 mg/m2 intravenously on days 1 to 5, and Ven 400 mg by mouth on days 1 to 14 per assigned dose schedule/level (42-day cycles × 8, or 28-day cycles × 12). During maintenance, the most common grade 3-4 adverse events were leukopenia, neutropenia, and thrombocytopenia, which were transient and manageable. Infections were uncommon (n = 4, all grade 1-2). The 1-year and 2-year moderate/severe chronic GVHD rates were 4% (95% confidence interval [CI], 0.3%-18%) and 22% (95% CI, 9%-40%), respectively. After a median follow-up of 25 months among survivors, the median overall survival (OS) was not reached. Among the 22 patients who received Ven/Aza maintenance, the 2-year OS, progression-free survival, nonrelapse mortality, and cumulative incidence of relapse rates were 67% (95% CI, 43%-83%), 59% (95% CI, 36%-76%), 0%, and 41% (95% CI, 20%-61%), respectively. Immune monitoring demonstrated no significant impact on T-cell expansion but identified reduced B-cell expansion compared with controls. This study demonstrates prophylactic Ven/Aza maintenance can be safely administered for patients with high-risk MDS/AML, but a randomized study is required to properly assess any potential benefit. This trial was registered at www.clinicaltrials.gov as #NCT03613532.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Garcia JS, Kim HT, Murdock HM, et al. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024. PMID: 38197938. doi:10.1182/bloodadvances.2023012120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。